Revolution Medicines Stock Surges 132% on Daraxonrasib Trial Data
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
Metastatic Pancreatic Cancer
DiseaseRelated News
Biotech IPOs Surge 55% as Nvidia Exit and ARK Buy Split AI Drug Discovery Stocks
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
Recent Cancer Research Advances Span Treatments and Biomarkers
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
Revolution Medicines' Daraxonrasib Cuts Death Risk 60% in Pancreatic Cancer; EMA Starts Rolling Review
Daraxonrasib reduced death risk by 60% versus chemo in Phase 3 pancreatic cancer trial (median OS 13.2 vs 6.7 months). EMA began rolling review; zoldonrasib combo data presented at ESMO GI.
FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer
The FDA approved Novocure's Optune Pax for locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel, based on PANOVA-3 data showing improved overall survival. The device also earned a CE mark in Europe, with a planned launch in Germany.
Experimental Pill Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer Trial
An experimental pill called daraxonrasib nearly doubled survival for patients with advanced pancreatic cancer in a clinical trial, marking a significant advance for a deadly disease. The drug targets a mutated protein previously considered "undruggable" and reduced the risk of death by 60% compared to chemotherapy.
Revolution Medicines says daraxonrasib extended survival in phase 3 pancreatic cancer study
Revolution Medicines said daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a phase 3 pancreatic cancer study. The company plans to seek FDA approval for the KRAS-targeting pill.
Daraxonrasib Phase III trial showed 13.2-month median overall survival in metastatic pancreatic cancer
Daraxonrasib showed median overall survival of 13.2 months versus 6.7 months for chemotherapy in a Phase III trial in previously treated metastatic pancreatic adenocarcinoma. The once-daily pan-RAS(ON) inhibitor was generally well tolerated, and the company plans to seek FDA approval.
Revolution Medicines Begins Phase 3 Trial for Daraxonrasib in First-Line Pancreatic Cancer
Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.
AIM ImmunoTech Announces Phase 2 Ampligen Trial Milestones for Pancreatic Cancer
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07707674 |
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07587827 |
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07409272 |
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT07262567 |
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT07122466 |
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy |
ACTIVE_NOT_RECRUITING | |
| NCT07026916 |
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer |
WITHDRAWN | PHASE2 |
| NCT06967233 |
Multimodal Managements for Metastatic Pancreatic Cancer. |
COMPLETED | |
| NCT06951997 |
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer |
RECRUITING | PHASE2 |
| NCT06861088 |
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT06843551 |
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation |
RECRUITING | PHASE2 |